"本研究計畫旨在經由一系列的生物體外 (in vitro) 與生物體內 (in vivo) 的試驗，瞭解是否單一高硫酸基含量海藻寡醣可以呈現較優越的抗病 毒活性與抗血小板凝集反應活性，並且期待瞭解是否與所增加的硫酸基 含量有一定的關係。 第一年將探討以紅藻 (如龍鬚菜)、褐藻 (如馬尾藻)、與綠藻 (如石蓴)製備之分離純化的單一海藻寡醣，並將個別海藻寡醣之硫酸基含量提升至 10%-30%的濃度的最適反應條件，並對重要的高硫酸基含量海藻寡醣將以NMR與MS等儀器確認其詳實之分子組成與基本結構，以供做為後續生理 活性測試之用。 第二年擬以前述具應用潛力含高量 (12-30%) 硫酸基海藻寡醣進行 抗血小板凝集試驗(與本系江孟燦老師合作)與抗病毒測試反應(與本系 吳彰哲老師合作) 等之in vitro生物活性效果評估，並確認具有顯著生理 活性效果者，即檢出供做後續於第三年計畫之動物實驗中用為測試的主要 對象。 第三年擬將已經in vitro試驗評估適宜之含高量 (12-30%) 硫酸基海藻 寡醣進行抗血小板凝集試驗(與本系江孟燦老師合作)與抗病毒(與本系 吳彰哲老師合作)等之in vivo 動物實驗的反應效果評估，並將嘗試瞭解動物實驗中之反應機制。以做為未來實際應用於藻類寡醣保健食品生產時的 重要參考基礎。" "The topic of this research project is through a series in vitro and in vivo experiments to evaluate if single high-sulfated group contained algal oligosaccharides (AOSs) could perform superior antiviral activity (JEV and entervirus) and anti-platelet aggregation activity while compare to none added one. And the possible reacting mechanisms mentioned also will be studied to realize that if the better performance on the bioactivities is correlated to the extra sulfated group contents. In the first year, the single AOS will be prepared from red alga (such as Gracilaria sp.), brown alga (such as Sargassum sp.), and green alga (such as Ulva sp.) with crude enzymes from strains MA103 and MAEF108 of this lab. And the content of sulfated group of each AOS is going to increasing from 12% to 30% (as some heparin had). The optimal reacting conditions will be studied also for future processing. To certain important high-sulfate-content AOS, their molecular composition and structure will be measured by NMR and MS for further understanding on their biological activities. In the second year, 12-30% sulfated-group contained AOS will be examined for their anti-platelet aggregating effect (cooperated with Prof. M. T. Chiang in this Dept.) and antiviral activity (cooperated with Assoc. Prof. C. J. Wu in this Dept.) in vitro. And 2-3 higher sulfated content AOS, with best performed on those biological activities, will be produced to appropriate amounts for further animal experiments in the third year. In the third year, those 2-3 higher sulfated content AOS with best anti-platelet aggregating effect and/or antiviral activities are used to examined their in vivo performance in suitable animal experiments, cooperated with Prof. M. T. Chiang and Assoc. Prof. C. J. Wu, respectively. And the reacting mechanisms will also be studied for more understanding the role of these higher sulfated content AOS. And these achievements will be important assets in the future practical production for algal health food products."
Algal oligosaccharides (OS)
Red alga Gracilaria sp.
Brown alga Sargassum sp.
Green alga Ulva lactuca
Anti-coagulant of blood activity
anti-platelet aggregation activity